Platelet-Lysate-Expanded Mesenchymal Stromal Cells for the Treatment of Resistant GVHD  by Lucchini, G. et al.
Oral Presentations S16946
EARLY POST-TRANSPLANT WHOLE TUMOR CELL VACCINATION ELICITS
ANTI-TUMOR T CELL RESPONSES IN PATIENTS WITH ADVANCED
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
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Vaccinationwithwhole leukemia cells early after allogeneic hemato-
poietic stem cell transplantation (HSCT) may facilitate expansion of
anti-tumor responses. We tested this hypothesis by initiating a phase
I study to vaccinate CLL patients between days 30-100 following re-
duced-intensity (RIC)-HSCT. One cycle of 6 vaccines consisted of
1x107 irradiated autologous CLL cells admixed with irradiated K562
bystander cells secreting the cytokine adjuvant GM-CSF. Of 20 en-
rolled patients, 15 initiated vaccination. Four of 20 developed GvHD
before day 45, precluding vaccination. At a median of 21 months fol-
low-up, all vaccinated patients remain disease-free–an improvement,
comparedwith ahistoric relapse rate of 50%at2 years forCLLpatients
undergoing RIC-HSCT at our center. We thus compared T cell im-
mune reconstitution of study subjects with CLL patients who had un-
dergone RIC-HSCTwithout vaccines. Recovery of peripheral CD31
T cell numbers until d100 was similar between vaccinated subjects and
15 transplanted/non-vaccinatedCLLcontrols. Specificity of the recon-
stituted T cells in vaccinated patients, however, was consistently di-
rected against autologous tumor cells. Five of 5 vaccinated patients
demonstrated increased circulating IFN-g secreting CD81 T cells
by ELISPOT against autologous tumor (mean of 516 vs 184 spots/
106 CD81 T cells at d60 (post-vaccine) vs d30 (pre-vaccine)), but not
against autologous hematopoietic cells (PHA blasts, 57 spots/106
CD81 cells, d60) nor autologous non-hematopoietic cells (fibroblasts,
108 spots/106 CD81 cells, d60). In contrast, 5 of 5 controls (1HSCT,
no vaccine) did not have expanded anti-tumor responses at d60 (mean
51 spots/106CD81 cells).Moreover, withGvHD,T cell reactivity de-
veloped against autologous PHA blasts and fibroblasts (mean 438 and
434 spots/106 CD81 cells at d90, respectively). After vaccination, tu-
mor-reactiveCD81Tcellswere consistently polyfunctional, secreting
high levels ofGM-CSF,TNF-a, and IL-2.By limiting dilution,we iso-
latedT cell clones fromPBMCof 4 vaccinated subjects, and confirmed
that 30-50% of T cell clones demonstrated specific recognition of au-
tologous CLL, but not of alloantigen-bearing cells. Our studies reveal
that early post-transplant CLL/GM-K562 vaccination is associated
with induction of immunity against recipient CLL cells, and suggest
that this is an effective strategy for tipping the balance of immunity in
favor of GvL following nonmyeloablative HSCT.HEMATOPOIESIS/MESENCHYMAL CELLS47
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Mesenchymal stromal cells (MSC) are multipotent cells with im-
munomodulatory properties, capable to escape immune rejection al-
lowing their use in an HLA-mismatched setting.
We describe a multi-centre experience, which started in May 2008
and relied on the use GMP-grade unrelated HLA-disparate donors’
bonemarrow-derivedMSCs, expanded in Platelet-Lysate -containing
medium. 10 pts (4 to 15 years) transplanted for malignant (N5 8) or
non-malignant (N5 2) diseases, received ivMSCs for acute or chronic
grade I-IV GvHD, which was resistant to multiple lines of immuno-
suppression.TwentyMSC infusions were given to 10 pts. Themedian
dose per infusion was 1.2 106/kg. Response to treatment was evalu-ated 28 days after infusion.Overall response (OS) was 75%,with com-
plete response (CR) in 25%of the cases.We further developed a phase
1 study from August 2009 in order to allow an earlier use of MSCs, as
second line treatment after steroid failure. 13 pts (7 adults, 5 pediatric)
aged 1-58 years received iv MSCs infusions for steroid resistant acute
or chronic GvHD grade II-IV. HSCT was performed for malignant
(N5 10) or nonmalignant diseases (N5 3).GvHDpresented as acute
in 11 cases and chronic in 2, it involved a single organ in 7 pts (5 skin, 2
gut) and multiple organs in the other cases. Pts received 2 to 6 MSC
infusions at 1x 106/kg recipient body weight MSCs for each infusion.
OS was 70 %, and CR 30%. None of the patients affected by chronic
GvHDshowedanybenefit.BothskinandgutGvHDpresentedabetter
response rate, skin showing an earlier response (2 to 4 days) compared
to gut (5 to 7 days). Patients with multiple organ involvement showed
aworse response. In all 34 treated pts, no side affects were observed af-
terMSCinfusion.All responder pts could eventually taper ongoing im-
munosuppression. Seven pts presented GvHD recurrence 2-5 months
after infusion. Four pts developed chronic GvHD. 29 out of 34 treated
patients are alive and in complete remission from their disease with an
average follow-up of 15.5 months from MSC infusion (range 2-29
months). One pt is alive with overt relapse of ALL, 1 pt died from
GvHD complications, 3 pts died from infectious diseases. The present
study underlines the safety of PL-expanded MSC use in children and
adults. MSC efficacy seems to be greater in acute than in chronic
GvHD, it represents anoptimal second-line strategy and it could be ef-
fective even after failure of multiple lines of immunosuppression.48
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Background: Graft-promoting effects of mesenchymal stem cells
(MSCs) may be particularly useful for transplants showing delayed
engraftment, such as unrelated umbilical cord blood transplantation
(UCBT). Inherently low immunogenicity of MSCs may open the
possibilities to use universal donor MSCs. We here report the use
of third party UCB-derived MSCs to enhance engraftment and to
prevent rejection in patients undergoing unrelated UCBT.
Methods: Seven patients with high-risk acute leukemia enrolled in
the study and the outcome was compared with 22 historical controls
with high-risk acute leukemia given UCBTwithout MSCs. UCB-de-
rived, ex vivo-expandedMSCswere infused at a target dose of 1 106/
kg in 4 patients and 5  106/kg in 3 patients. On day 0, patients re-
ceived the specified MSC dose just before infusion of the UCB unit.
Results:There was no acute toxicity related to the infusion ofMSCs
andno sign of ectopic tissue formation.Therewere no significant dif-
ferences for age, gender, transplant indication, and number of
CD341 cells and nucleated cells infused between MSC group and
control group. Neutrophil engraftment occurred at a median of 19
days (16-21) forMSCgroup, and at amedian 17 days (13-44) for con-
trol group (P5 0.76). The probability of achieving a platelet count$
20  109/L by 100 days after transplant was 100% at a median of 47
days (33-80) for MSC group, and 76.5% at a median of 51 days (19-
231) for control group (P5 0.41). In comparison to controls (13.6%
graft failure), all patients who were given MSCs engrafted success-
fully. The incidence of grade III-IV acute GvHD was 14.3% for
MSC group and 5.9% for control group (P 5 0.51). The incidence
of extensive chronic GvHD was not statistically different between
MSC (14.3%) and control group (18.8%, P5 0.79). The incidences
of treatment-related mortality (TRM) within 100 days of transplant
and veno-occlusive disease (VOD) were 18.2% and 22.7% in control
group,whereas none of the patients ofMSCgroup experiencedTRM
or VOD. Although there was a trend toward improved 2-year event-
free survival after transplant in MSC group (75.0%) compared with
control group (54.5%), it was not statistically significant (P5 0.33).
